Start Date
March 31, 2025
Primary Completion Date
September 30, 2026
Study Completion Date
December 30, 2026
Sotorasib
Sotorasib is administered at a dose of 960 mg (8x 120 mg) orally, once daily until progression or unacceptable toxicity.
Lenvatinib
Lenvatinib is administered at a dose of 20 mg orally (2x 10 mg), once daily until progression or unacceptable toxicity.
Medical University of Innsbruck / UK für Innere Medizin V, Innsbruck
University Hospital of Munich (LMU), Department of Medicine V (Pneumology/Thoracic Oncology), Munich
Alicante University Dr Balmis Hospital ISABIAL, Alicante
Ico Badalona - Hospital Germans Trias I Pujol, Badalona
Hospital Universitario Lucus Augusti, Lugo
Hospital Universitario de Salamanca, Salamanca
Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife
Hospital Universitario Virgen Del Rocio, Seville
Hospital Universitario de Toledo, Toledo
Hospital Universitario Y Politécnico La Fe, Valencia
Istituto Oncologico della Svizzera Italiana, Bellinzona
Kantonsspital Graubünden, Chur
HFR Fribourg, Fribourg
HUG, Geneva
Kantonsspital Winterthur, Winterthur
Collaborators (1)
Amgen
INDUSTRY
Eisai Inc.
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK